Relative dose intensity of R-CHOP therapy and patient outcomes in advanced follicular lymphoma

Hematol Oncol. 2019 Aug;37(3):303-307. doi: 10.1002/hon.2614. Epub 2019 Apr 26.

Authors

Tatsuya Konishi^{1

2}, Yusuke Kanemasa¹, Yuki Sasaki³, Toshihiro Okuya¹, Tsukasa Yamaguchi¹, Chikako Funasaka¹, Tatsu Shimoyama¹, Yasushi Omuro¹

Affiliations

¹ Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
² Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
³ Department of Clinical Research, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.

PMID: 30933366
DOI: 10.1002/hon.2614

No abstract available

Publication types

Clinical Trial
Letter
Multicenter Study

MeSH terms

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived / administration & dosage
Antibodies, Monoclonal, Murine-Derived / adverse effects
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Cyclophosphamide / administration & dosage
Cyclophosphamide / adverse effects
Disease-Free Survival
Doxorubicin / administration & dosage
Doxorubicin / adverse effects
Female
Follow-Up Studies
Humans
Lymphoma, Follicular / drug therapy*
Lymphoma, Follicular / mortality*
Male
Middle Aged
Prednisone / administration & dosage
Prednisone / adverse effects
Retrospective Studies
Rituximab
Survival Rate
Vincristine / administration & dosage
Vincristine / adverse effects

Substances

Antibodies, Monoclonal, Murine-Derived
R-CHOP protocol
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone